Treatment Guidelines for Falciparum Malaria

First-Line Treatment Options

Artemether-lumefantrine (AL) is recommended as first-line treatment for uncomplicated P. falciparum malaria, with dosing of 4 tablets at 0 hours, 4 tablets at 8 hours on day 1, then 4 tablets twice daily on days 2 and 3. 1, 2
AL must be taken with a fatty meal or drink to enhance absorption, as inadequate fat intake can result in subtherapeutic drug levels and treatment failure. 1, 2
Dihydroartemisinin-piperaquine (DP) is an alternative first-line ACT, dosed as 3 tablets daily for 3 days (36-75 kg) or 4 tablets daily for 3 days (>75 kg), taken in fasting condition. 1, 2
Both AL and DP demonstrate high efficacy for uncomplicated falciparum malaria with 7-day parasitological cure rates of 98.4% and 28-day cure rates of 96%. 3

For patients in whom ACTs are contraindicated (e.g., risk of QT prolongation), atovaquone-proguanil is recommended as second-line treatment. 4, 5

For severe P. falciparum malaria, intravenous artesunate is the first-line treatment at a dose of 2.4 mg/kg IV at 0, 12, and 24 hours, then continued daily until parasite density is <1%. 4, 2
Once the patient improves clinically (parasitemia <1%) and can take oral medication, treatment should be completed with a full course of oral ACT. 6, 4
If intravenous artesunate is unavailable, intravenous quinine is the second-line option, dosed at 20 mg salt/kg over 4 hours (loading dose) followed by 10 mg/kg over 4 hours starting 8 hours after initiation and then every 8 hours. 4

ACTs provide rapid parasite clearance with fever clearance times around 36.8 hours and parasite clearance times around 41.5 hours. 3
Post-artemisinin delayed hemolysis (PADH) is a potential adverse effect that requires monitoring on days 7, 14, 21, and 28 after treatment. 5, 2
Both artemether-lumefantrine and dihydroartemisinin-piperaquine can cause QTc interval prolongation and should be avoided in patients at risk for QTc prolongation or taking medications that prolong QTc. 1, 2

Failure to ensure adequate fat intake with artemether-lumefantrine administration can result in subtherapeutic drug levels and treatment failure. 1, 2
Delayed diagnosis and treatment of P. falciparum malaria is associated with increased mortality. 2
Quinine has significant adverse effects including cinchonism (tinnitus, vertigo, headache), hypoglycemia, and potential for serious hematologic reactions including thrombocytopenia. 4